Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Sky One Medical has obtained approval from the State Food and Drug Administration in the People's Republic of China for four new drugs, Tobramycin eye drops, compound Zinc Sulfate eye drops, Ofloxacin suppositories and Ofloxacin gels.
Subscribe to our email newsletter
The new approvals bring the total number of China Sky One’s externally used products to 53 and its total marketed products to 102, giving the company one of the most comprehensive pharmaceutical product portfolios in China.
China Sky One is still aggressively seeking approval for other drugs with large market potential. By the end of 2008, the company is expected to have a total 34 new drugs submitted to the State Food and Drug Administration for approval.
Yan-qing Liu, chairman, CEO and president of China Sky One Medical, said: “These four products in China have an extensive market and China Sky One expects to be able to quickly launch them and expand market share through our extensive sales network and experienced management team.”